MarketInOut Stock Screener Log In | Sign Up
 

Novo Nordisk A/S Series B

OTC • Healthcare • Drug Manufacturers - General • Quote as of 05/22/2026
Novo Nordisk A/S Series B stock price and volume chart

Company Profile

IndustryDrug Manufacturers - General
SectorHealthcare
ExchangeOTC
Market Capitalization195,354 mln
Float3,186 mln
Earnings Date08/05/2026

EPS

4.26
Solid

P / E

10.28
Fair value

Piotroski F-Score

6 / 9
Solid

Beneish M-Score

-2.56
Likely reliable

1-Year Forecast

53.85
Attractive

Relative Strength

34 / 100
Underperforming

Business Description

Founded in Denmark in 1923, Novo Nordisk is a global pharmaceutical company best known for its treatments targeting diabetes and obesity, as well as rare conditions affecting the blood and hormonal system. The company develops and sells a range of medicines and delivery devices, including smart insulin pens and dosing tools, distributed across markets in North America, Europe, Asia, Latin America, and beyond.

Key Fundamentals

EPS4.26
P/E10.28
ROE70.46
RPS11.48
ROIC24.58
ROA23.85
Interest Cover61.30
EBITDA, mln28,236
EV / EBITDA8.24
EV / EBIT9.37
Revenue, mln51,057
EV / Revenue4.56

Financial Strength

Altman Z-Score3.92
Piotroski F-Score 6 / 9
Beneish M-Score-2.56
Price to Lynch Fair Value0.49
Price to Graham Number2.82
1-Year Target Price53.85
Shiller PE Ratio20.41

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -2.05% 38 / 100   
1 Month 13.41% 83 / 100   
2 Months -11.96% 34 / 100   
6 Months -8.49% 33 / 100   
1 Year -35.05% 18 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Contact Us